Press Release Details
Twist Bioscience to Report Fiscal 2019 First Quarter Financial Results on Thursday, February 7, 2019
The call can be accessed by dialing (866) 688-0947 (domestic) or (409)
217-8781 (international) and refer to the conference ID 7382069. A
telephonic replay of the conference call will be available beginning
approximately four hours after the call through
About
Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005094/en/
Source:
Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com